

National Anti Doping Agency
J.L.N Stadium, Hall No. 103-104, First Floor,
Lodhi Road, New Delhi 110 003
Telefax: 011-24368274

To,

Date: 20.02.2025

Mr. Ravinder Singh,
Sports- Kickboxing,
S/o Sh. Hamir Singh,
R/o Jaawandhe Patti, Mehlan,
Sangrur, Punjab-148001.
[Email- ravisinghboxer0@gmail.com](mailto:Email-ravisinghboxer0@gmail.com)

Subj: Decision of the Anti-Doping Disciplinary Panel Case No.- 30. ADDP. 2024

NADA VS. Mr. Ravinder Singh (ADAMS ID –SIRAMA86350)

The order containing the decision of the Anti-Doping Disciplinary Panel dated 18.02.2025 in respect of the final hearing of the above case held on 14.01.2025 is enclosed.

Please note that according to Article 13.2.2 of Anti-Doping Rules of NADA 2021, **the time to file an appeal to the National Anti-Doping Appeal Panel shall be twenty-one (21) days from the date of receipt of this decision by the appealing party.** The appeal may be filed by email at antidoping-panel@gov.in or may be filed directly at the office of the Anti- Doping Panel at J.L.N. Stadium, Ground Floor, Staircase No. 5, Near AICS Office, Lodi Road, New Delhi- 110003.

WADA and the International Federation have a right to appeal against the decision in accordance with Anti-Doping Rules.

Also please note that according to Article 10.7.1- **(Substantial Assistance in Discovering or Establishing Anti-Doping Rule Violations)**- Any period of Ineligibility imposed may be partially suspended if you assist NADA in uncovering and/or establishing an ADRV by another Athlete or Athlete Support Personnel pursuant to Article 10.7.1 ADR. Further, the athlete is subjected to a doping control test during the ineligibility period, therefore, the athlete is required to update his residential address as and when changed.

Copy of the NADA Anti-Doping Rules 2021 may be downloaded from NADA website at the following link: - <https://nadaindia.yas.gov.in>

The receipt of this communication may be acknowledged.

Encl: 06 Sheets.



Sr. Programme Associate (Legal)

Copy forwarded together with the copy of the order containing the decision of the Anti-Doping Disciplinary Panel for information and action deemed necessary:

1. The World Anti-Doping Agency, Stock Exchange Tower, 800 Place Victoria (Suit 1700) P. O. Box 180, Montreal (Quebec), H4Z 1B7, Canada.
2. Wako India Kickboxing Federation, Office No. 7, 1st Floor, Achievers Center Point Mall, Sector-49, Faridabad-121001, Haryana.
3. World Association of Kickboxing Organizations, Via Passione, 8 20122 Milan, Italy.

BEFORE THE ANTI-DOPING DISCIPLINARY PANEL

JLN Stadium, Lodhi Road New Delhi 110003

Case No. 30/ADDP/2024

**In the matter of Mr. Ravinder Singh for the violation of Articles 2.1 & 2.2 of
National Anti-Doping Rules, 2021**

(PROCEEDINGS CONDUCTED THROUGH VIRTUAL MODE)

Quorum: Mr. Chaitanya Mahajan, Chairperson, ADDP

Dr. D.S. Arya, Medical Member, ADDP

Ms. Archana Surve, Sports Member, ADDP

Present: Mr. Yasir Arafat (Counsel, NADA)

Mr. Ravinder Singh (Athlete)

JUDGEMENT DATED 18.02.2025

A. The present proceedings before this Anti-Doping Disciplinary Panel “ADDP” constituted under the National Anti-Doping Rules **Article 8** emanate from the violation of the National Anti-Doping Rules 2.1 (Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete’s Sample) & 2.2 (Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method). These are referred to as “**the ADR**” in this order. Capitalized terms used, but not defined in this letter, are as defined in the ADR against Mr. Ravinder Singh “**The Athlete**”. The athlete is a “**Kickboxing**” and his date of birth as stated by him in the Dope Control Form (“**DCF**”), to be **10.05.1991**.

B. That the brief facts of the case are as follows:

1. That on 10.02.2024, a NADA Doping Control Officer (“**DCO**”) collected an in-competition urine sample from the athlete at **Delhi**,

during the “**3rd WAKO INDIA OPEN INTERNATIONAL KICKBOXING TOURNAMENT**” Assisted by the DCO, the athlete split the sample into two separate bottles, which were given reference numbers **A 6554254** (the "A sample") and **B 6554254** (the "B sample"). The sample was transported to the World Anti-Doping Agency ("WADA")-accredited Laboratory, National Dope Testing Laboratory, Delhi. The Laboratory analysed the A sample in accordance with the procedures set out in WADA's International Standard for Laboratories. Analysis of the A sample returned an Adverse Analytical Finding ("AAF") for the following substance:

- **Drostanolone metabolite 3alpha-hydroxy-2alpha-methyl5alpha-androstan-17-one - Anabolic Androgenic Steroid**
- **Stanozolol metabolites 3-hydroxy stanozolol, 16 beta-hydroxy stanozolol, Stanozolol-1N-glucuronide - Anabolic Androgenic Steroid.**

2. The athlete was notified of the adverse analytical findings in sample **no. 6554254** via notification dated 03.04.2024. The sample confirmed the Adverse Analytical Finding on 01.04.2024, whereby the athlete was informed about the AAF in his sample reports. The analysis also highlighted the violation of Article 2.1 and Article 2.2 of the NADA Anti-Doping Rule, 2021, due to the presence of **Anabolic Androgenic Steroid S1 Drostanolone metabolite 3alpha-hydroxy-2alpha-methyl5alpha-androstan-17-one - Anabolic Androgenic Steroid and Stanozolol metabolites 3-hydroxy stanozolol, 16 beta-hydroxy stanozolol, Stanozolol-1N-glucuronide - Anabolic Androgenic Steroid.**

3. The athlete was subsequently served with a Notice of Charge, bearing **F. No. K/10/2024-SPO**, dated 27.05.2024. This Notice of Charge, issued under the NADA Anti-Doping Rules, 2021, accused the athlete of violating **Rule 2.1** and **Rule 2.2**.
4. The Athlete was notified through a letter dated 17.10.2024 that a Hearing Panel had been constituted to address the alleged anti-doping rule violation. The notification informed the Athlete of his right to respond to the charges and the potential consequences. It also indicated that the Athlete could submit written submissions, along with all supporting documents, to the Anti-Doping Disciplinary Panel within twenty (20) days from the receipt of the notice.
5. The hearing was held through video conferencing on 14.01.2025 by the Hearing Panel constituted under the Rules. Mr. Yasir Arafat Law officer presented the case on behalf of NADA and the Athlete appeared in person, after concluding the hearing the judgment was reserved.

C. ANTI-DOPING RULE VIOLATION(S) COMMITTED

1. The sample was transported to the World Anti-Doping Agency ("WADA")-accredited Laboratory, National Dope Testing Laboratory, Delhi. The Laboratory analysed the A sample in accordance with the procedures set out in WADA's International Standard for Laboratories. Analysis of the A sample returned an Adverse Analytical Finding ("AAF") for the following substance: **Anabolic Androgenic Steroid S1 Drostanolone metabolite 3alpha-hydroxy-2alpha-methyl5alpha-androstan-17-one - Anabolic Androgenic Steroid and Stanozolol metabolites 3-hydroxy stanozolol, 16 beta-hydroxy stanozolol, Stanozolol-1N-glucuronide - Anabolic Androgenic Steroid**

2. The said substances, **Anabolic Androgenic Steroid S1 Drostanolone metabolite 3alpha-hydroxy-2alpha-methyl5alpha-androstan-17-one - Anabolic Androgenic Steroid**, and **Stanozolol metabolites 3-hydroxy stanozolol, 16 beta-hydroxy stanozolol, Stanozolol-1N-glucuronide - Anabolic Androgenic Steroid**, is listed under S1 of WADA's 2023 Prohibited List as a non-specified substance.
3. The initial review of the A sample, as per **Article 7.2** of NADA and **Article 5.1.1** of the International Standards for Result Management ("ISRM"), shows that Athlete did not have Therapeutic Use Exemption (TUE); there was no apparent deviation from the International Standard for Testing and Investigation ("ISTI") or the International Standard for Laboratories ("ISL") that could undermine the validity of the AAF; and the AAF had not been caused by ingestion of the relevant Prohibited Substance through a permitted route.
4. That the athlete is in violation of the National Anti-Doping Rules **2.1** (Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's Sample) & **2.2** (Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method).

D. APPLICABLE CONSEQUENCES:

1. As the record indicates the athlete have no prior ADRVs, therefore in the event that the asserted ADRVs are upheld, NADA, India will seek the following proposed Consequences:
 - Disqualification of results in the Event during which the ADRV occurred and in Competitions subsequent to Sample collection or commission of the ADRV with all resulting Consequences including forfeiture of any medals, points and prizes;

- A period of Ineligibility subject to potential elimination, reduction or suspension pursuant to Article 10 of the NADA ADR, of four (4) years.
- Automatic publication of sanction.

E. Submission made by the Athlete are reproduced herein

1. The Athlete has admitted to the use of the prohibited substance but maintained that he was unaware of its nature or composition of the substance. The Athlete stated that he did not have any knowledge regarding whether the substance contained any banned ingredients or whether it could have any implications under the Anti-Doping Rules.
2. Furthermore, the Athlete clarified that his decision to use the substance was solely based on the recommendation of a Senior Athlete. However, the Athlete did not provide any details regarding the identity of this Senior Athlete.

F. Submission made by NADA: -

1. As the Athlete has admitted to the commission of an Anti-Doping Rule Violation (ADRV), NADA submits that the violation stands established, and therefore, it has no further substantive submissions to make in this regard.

G. Observation of the ADDP

1. After reviewing the submissions of both parties, the ADDP concludes that the conduct of the athlete led to the Anti-Doping Rule Violation.
2. The Panel has observed that, in this case and in multiple other instances, a major contributing factor to Anti-Doping Rule Violations is the lack of awareness among athletes regarding the implications of such violations and the Anti-Doping Rules set forth by NADA.

3. The Panel recommends that NADA implement awareness programs aimed at athletes at the grassroots level, focusing on educating them about the Anti-Doping Rules. These programs should involve collaboration with the respective sports associations to ensure effective and widespread dissemination of information throughout the sporting community.

H. Finding of the ADDP

In view of the above-mentioned facts, circumstances, precedents, and rules, **it is held that the athlete has violated Article 2.1 and Article 2.2 of the NADA ADR, 2021. he is hereby sanctioned with an ineligibility of 4 years as per Article 10.2.1.1 of the NADA ADR, 2021, beginning form the date of Provisional Suspension i.e. 03.04.2024.**

I. Disqualification of Result

The ADDP directs that, in accordance with Article 10.10, all competitive results obtained by the athlete from the date of sample collection, i.e. 10.02.2024, shall stand disqualified, with all resulting consequences, including forfeiture of medals, points, and prizes.



Mr. Chaitanya Mahajan
(Chairperson)



Dr. D.S. Arya
(Medical Member)



Ms. Archana Surve
(Sports Member)